Functional Characterization of Organoids Derived From Irreversibly Damaged Liver of Patients With NASH

Abstract

Expansion of primary liver stem cells/organoids derived directly from irreversibly damaged liver from patients with NASH opens up experimental avenues for personalized disease modeling and drug development that has the potential to slow human NASH progression and to counteract NASH-related SARS-CoV-2 effects.